Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673
Malcolm A. Smith, Oliver A. Hampton, C. Patrick Reynolds, Min H. Kang, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, Jianrong Wu, Raushan T. Kurmasheva, David A. Wheeler, Peter J. Houghton
Resultado de la investigación: Article › revisión exhaustiva
Profundice en los temas de investigación de 'Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673'. En conjunto forman una huella única.